14th EANO Annual Meeting 2019

September 19-22, 2019
Lyon, France

Representatives:
Juergen Gamer, Ph.D., VP Business Development
Ulrike Jaegle, Ph.D., VP Regulatory Affairs
Andriy Krendyukov, M.D., MBA, VP Medical Affairs
Christian Merz, Ph.D., Head of Cellular Analytics
Irina Odnoletkova, Ph.D., MBA, VP Health Technology Assessment

Poster Presentation on September 21, 3:45-5:15 pm (Poster Session 2):
"Differential methylation of a single CpG site in the CD95 ligand promoter affects gene activity and correlates with invasiveness of glioma cells"

 

5th CRI-CIMT-EATI-AACR International Cancer Immunotherapy Conference

September 25-28, 2019
Paris, France

Representatives:
David Richards, Ph.D., Head of Immunology
Julian Sefrin, Ph.D., Senior Scientist Immunology

Poster Presentation: "The hexavalent CD40 agonist HERA-CD40L induces a productive T cell-mediated anti-tumor immune response and shows superior activity in comparison to benchmark CD40 agonistic antibodies"

 

ESMO 2019

September 27 - October 1, 2019
Barcelona, Spain

Representative: Andriy Krendyukov, M.D., MBA, VP Medical Affairs

ESMO Colloquium: Recurrent glioblastoma management: Challenges and opportunities
September 30, 6:30-8:00 pm, Salamanca Auditorium (Hall 3)

This educational activity is provided by ESMO and supported by Apogenix AG.

 

4th Biennial World Summit of Brain Tumour Patient Advocates

October 9-12, 2019
Bethesda, MD, USA

Representative: Irina Odnoletkova, Ph.D., MBA, VP Health Technology Assessment

 

Festival of Biologics

October 15-17, 2019
Basel, Switzerland

Representatives:
Katharina Billian-Frey, Ph.D., Senior Scientist Drug Discovery/Protein Engineering
Oliver Hill, Ph.D., VP Drug Discovery/Lead Optimization

Presentation on October 16, 12:05 pm:
"HERA-CD40L: A unique hexavalent CD40 agonist for cancer immunotherapy"

 

ISPOR Europe 2019

November 2-6, 2019
Copenhagen, Denmark

Representative: Irina Odnoletkova, Ph.D., MBA, VP Health Technology Assessment

Poster Presentation on November 4, 3:30-7:00 pm (Poster Author Discussion Hour: 6:00-7:00 pm):
"Therapeutic Benefit of Orphan Drugs in Oncology: Evidence at the Point of European Marketing Authorisation"

 

BIO-Europe 2019

November 11-13, 2019
Hamburg, Germany

Representatives:
Juergen Gamer, Ph.D., VP Business Development
Niclas Kneisel, Ph.D., Alliance Manager

 

11th Annual PEGS Europe

November 18-22, 2019
Lisbon, Portugal

Representatives:
Katharina Billian-Frey, Ph.D., Senior Scientist Drug Discovery/Protein Engineering
Oliver Hill, Ph.D., VP Drug Discovery/Lead Optimization

Presentation by Dr. Hill on November 22, 2:35 pm:
"HERA-GITRL: A Unique Hexavalent GITR Agonist for Cancer Immunotherapy"

 

SNO 2019 Annual Meeting

November 22-24, 2019
Phoenix, AZ, USA

Representative: Juergen Gamer, Ph.D., VP Business Development

 

19th Annual PepTalk

January 20-24, 2020
San Diego, CA, USA

Representative: Katharina Billian-Frey, Ph.D., Senior Scientist Drug Discovery/Protein Engineering